Abstract

New treatments for common neurodegenerative conditions such as Alzheimer’s and Parkinson’s Disease are urgently needed for our aging society. At the Alzheimer’s Research UK Oxford Drug Discovery Institute we are pursuing early drug discovery efforts on novel targets in neuroinflammatory and sub-cellular organelle dysfunction pathways. In addition to an introduction to our target evaluation and selection strategy, our latest efforts to discovery CNS-penetrant leads for the NLRP3 inflammasome will be presented.